RxDoctor Payments Data

Raza Hassan, MD

Cardiovascular Disease · Seneca, SCNPI 1912929282

Payments from drug & device makers

$6,179in general payments, 2019–2025

Across 295 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novartis$780
  • Johnson & Johnson$764
  • Amgen$653
  • Boehringer Ingelheim$353
  • Boston Scientific$334
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,158100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,179 in reported general payments places this provider in the 60th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$297,757
Medicare patients
1,941
Services billed
5,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban357$343,044
Repatha SureclickEvolocumab168$173,402
XareltoRivaroxaban111$109,737
JardianceEmpagliflozin43$49,598
Praluent PenAlirocumab50$47,060
EntrestoSacubitril/Valsartan38$35,597
NexlizetBempedoic Acid/Ezetimibe24$21,744
Ezetimibe485$15,968
VascepaIcosapent Ethyl32$14,588
Icosapent Ethyl42$11,923
BrilintaTicagrelor15$9,132
Flecainide Acetate181$5,371
Doxazosin Mesylate370$5,278
Metoprolol Succinate379$4,565
Atorvastatin Calcium340$4,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$185$343,044357 claims
Johnson & JohnsonXarelto$764$109,737111 claims
Boehringer IngelheimJardiance$353$49,59843 claims
NovartisEntresto$780$35,59738 claims
Esperion Therapeutics, Inc.Nexlizet$51$21,74424 claims
AstraZenecaBrilinta$97$9,13215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Seneca

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →